Skip to content

Cangrelor

    Brands

    DEA Class; Rx

    Common Brand Names; Kengreal

    • Antiplatelet Agents, Cardiovascular

    Injectable P2Y12 platelet inhibitor indicated as an adjunct to PCI in patients not already receiving an oral P2Y12 inhibitor or glycoprotein IIb/IIIa inhibitor
    Onset of platelet inhibitor occurs within 2 minutes of initiation of therapy and returns to normal within 1 hour of discontinuation
    Contraindicated in patients with active significant bleeding

    Indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor

    Significant active bleeding

    Hypersensitivity

    GUSTO trial data

    • Mild (14.9%)
    • Moderate (0.4%)
    • Severe/life-threatening (0.2%)

    TIMI trial data

    • Minor (0.6%)
    • Major (0.2%)

    Worsening renal function in patients with CrCl <30 mL/min (3.2%)

    Hypersensitivity

    Drugs that inhibit platelet P2Y12 function, increase risk of bleeding

    Increased risk of bleeding; bleeding events of all severities were more common with cangrelor than with clopidogrel

    Bleeding complications were consistent across a variety of clinically important subgroups

    Once therapy is discontinued, there is no antiplatelet effect after an hour

    There are no available data on use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes; untreated myocardial infarction can be fatal to pregnant women and fetus

    There are no data on presence of drug in human milk or animal milk, effects on breastfed infant, or on milk production; due to its short-half life, drug exposure is expected to be very low in breastfed infant

    Adults

    30 mcg/kg IV bolus; 4 mcg/kg/minute IV infusion.

    Geriatric

    30 mcg/kg IV bolus; 4 mcg/kg/minute IV infusion.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Infants

    Not indicated.

    Neonates

    Not indicated.

    Cangrelor

    injection, lyophilized powder for reconstitution

    • 50mg/vial